key: cord-1016593-48ikem45
authors: Irabien-Ortiz, Ángela; Carreras-Mora, José; Sionis, Alessandro; Tauron, Manel
title: Fulminant myocarditis and COVID-19. Response
date: 2020-06-19
journal: Rev Esp Cardiol (Engl Ed)
DOI: 10.1016/j.rec.2020.06.012
sha: 4843a11a683d8816c43abc827c1cb674fd1470d6
doc_id: 1016593
cord_uid: 48ikem45

nan

E-mail address: angelairabien@hotmail.com (Á. Irabien Ortiz).

First of all, the authors would like to thank Beuy et al. for the interest shown in our article. 1 We consider that the questions they raise are highly interesting and deserve further analysis and debate.

Unfortunately, the pathophysiology of this virus is still unknown. As described in the article, previous 

In the reported case, the diagnosis of myocarditis was based upon clinical data, imaging and biomarkers 4 of acute cardiac damage. Regarding the etiology of myocarditis, myocardial biopsy was not performed due to hemodynamic instability, significant coagulopathy, and subsequent improvement in cardiac function. Polymerase chain reaction (PCR) for viruses in the nasopharyngeal swab tested was positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and negative for adenovirus and influenza A and B viruses, with a positive epidemiological environment.

Therefore, when all this information was gathered together, the assumption of COVID-19 as the etiology of myocarditis was supported. We hope this adds some clarification to the comments by Beuy et al.

Fulminant myocarditis due to COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes